Related content

Phosphorylated/Activated HER2 as a Marker of Clinical Resistance to Single Agent Taxane Chemotherapy for Metastatic Breast Cancer

By Modi Shanu   DiGiovanna Michael   Lu Zhao   Moskowitz Chaya   Panageas Katherine   Van Poznak Catherine   Hudis Clifford   Norton Larry   Tan Lee   Stern David   Carter Darryl   Seidman Andrew  

Cancer Investigation, Vol. 23, Iss. 6, 2005-09 ,pp. : 483-487

Informa Healthcare

Access to resources Recommend Favorite

Treatment Choices for Second-Line Chemotherapy of Metastatic Breast Cancer

By Zielinski Christoph C.  

Breast Cancer Research and Treatment, Vol. 81, Iss. 1, 2003-01 ,pp. : 33-36

Springer Publishing Company

Access to resources Recommend Favorite

Ixabepilone for the treatment of taxane-refractory breast cancer

By Moulder Stacy L  

Future Oncology, Vol. 4, Iss. 3, 2008-06 ,pp. : 333-340

Future Medicine

Access to resources Recommend Favorite

Capecitabine monotherapy in patients with anthracycline-and taxane-pretreated metastatic breast cancer

By Lee S.-H.   Lee J.   Park J.   Park S.   Lee K.-E.   Lee S.   Nam E.   Park J.   Kim K.   Jung C.   Park Y.   Yoon S.   Kang W.   Lee M.   Park K.   Im Y.-H.  

Medical Oncology, Vol. 21, Iss. 3, 2004-09 ,pp. : 223-231

Humana Press, Inc

Access to resources Recommend Favorite

Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer

By Wist Erik   Sommer Hilde   Østenstad Bjørn   Risberg Terje   Bremnes Yngve   Mjaaland Ingvild  

Acta Oncologica, Vol. 43, Iss. 2, 2004-03 ,pp. : 186-189

Informa Healthcare

Access to resources Recommend Favorite